PCI Biotech: Exercise of employee share options, m

Oslo (Norway), 5 September 2017 - Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the "Company").

1.   Options exercised and mandatory notification of trade Participants in the Company's share option program have on September 5^th 2017 exercised a total number of 86,500 share options at a strike price of NOK 19.90, corresponding to a total number of 86,500 shares. All of the exercised share options expired on September 5^th 2017.

Out of the total number of exercised share options, 38,000 share options are exercised by the following primary insiders, who, in turn, have sold such number of shares in the market as is necessary in order to finance the cash and tax impact of the exercise:

Per Walday, CEO, exercised 16,000 share options at a subscription price of NOK 19.90 per share and has sold 14,428 shares at NOK 24.62 per share. After the transaction, Mr. Walday will hold 65,133 shares and 104,000 share options in the Company.

Anders Høgset, CSO, exercised 11,000 share options at a subscription price of NOK 19.90 per share and has sold 9,919 shares at NOK 24.62 per share. After the transaction, Mr. Høgset will hold 62,456 shares and 66,000 share options in the Company.

Kristin Eivindvik, PD, exercised 11,000 share options at a subscription price of NOK 19.90 per share and has sold 9,919 shares at NOK 24.62 per share. After the transaction, Ms. Eivindvik will hold 17,948 shares and 33,500 share options in the Company.

This announcement also represents a mandatory notification of trade, which is submitted by the Company on behalf of such primary insiders.

2.   Resolution to increase the share capital Following the exercise of share options on September 5^th 2017, the Company's Board of Directors, pursuant to an authorisation granted by the Company's Annual General Meeting on May 29th 2017, has decided to increase the Company's share capital with NOK 259,500 by issuing 86,500 new shares, each share of par value NOK 3.00. Subsequent to the transaction, the Company's share capital will be NOK 74,960,670 divided into 24,986,890 shares. The capital increase will result in gross proceeds of NOK 1,721,350.

Contact information:                  Ronny Skuggedal, CFO rs@pcibiotech.no Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.